Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
All content for The IMID Forum is the property of The Immune-Mediated Inflammatory Disease Forum and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025
The IMID Forum
28 minutes 57 seconds
3 months ago
Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025
Join Professor Peter Nash from Griffith University in Brisbane, and Dr Rodrigo Garcia‑Salinas from Hospital Italiano de La Plata in Argentina, as they discuss Dr Garcia-Salinas’ recent publication ‘Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns’.
The IMID Forum
Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.
